Replies to post #1770 on Insmed Inc (INSM)

[elmono]

thanks!

[io_io]

possible pricing -

I would expect easily $25k then, and rising every year. It's not possible to reach every patient, and TRCA will snare a few. But 3,000-4,000 within a couple of years does not seem at all a stretch. So maybe $100m on-label.

Does anyone think that off-label sales will begin immediately (in primary, rather than severe - yes I know there are other indications, but am thinking of the endos only for now) ? Any hard evidence in the endos' sphere ?